In an agency first, the FDA has cleared a system designed to clean out the complex inner channels of flexible endoscopes—a ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

The agency has also removed 91 federal sites previously listed on its “wall of receipts” for planned lease cancellations, ...

Abbott will be trying its hand in the growing field of intravascular lithotripsy, with a clinical study to examine an unnamed ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Surrozen is discontinuing its sole clinical-stage candidate and pivoting to its preclinical ophthalmology pipeline after the ...

After outlining plans nearly one year ago to take 23andMe private—and submitting multiple offers—co-founder and CEO Anne ...